Obesity is one of the leading drivers of steatotic (fatty) liver disease, especially metabolic dysfunction-associated steatotic liver disease (MASLD) a serious and growing condition now effecting 80-100 million adults across the U.S. Left untreated, MASLD can lead to cirrhosis, liver cancer, liver failure, and even death. But this progression is preventable with early intervention and equitable access to care.

Yet right now, Medicare beneficiaries, particularly older adults most vulnerable to MASLD, face unnecessary barriers to comprehensive obesity treatment. The Treat and Reduce Obesity Act (TROA) would change that by:

• Expanding Medicare access to intensive behavioral therapy delivered by dietitians and other providers who specialize in obesity care
• Finally allowing coverage of FDA-approved anti-obesity medications (AOMs) under Medicare Part D

This isn’t just about weight, it’s about access to proven, evidence-based care that can prevent disease, reduce costs, and save lives. Whether or not someone uses AOMs, they deserve comprehensive treatment options, not barriers. 

Join us in urging Congress to pass TROA and ensure Americans have the tools they need to treat obesity and protect their liver health.